Skip to content

Cross-Sequential iTBS and cTBS for Adolescent Depression: A Randomized Controlled Trial

Cross-Sequential iTBS and cTBS for Adolescent Depression: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125421
Enrollment
Unknown
Registered
2026-05-26
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Major Depressive Disorder

Interventions

Cross-sequential sham stimulation group:Sham stimulation intervention

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 12 and 18 years, regardless of gender. 2. meet the diagnostic criteria for depressive disorder according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10); 3. HAMD-17 total score >= 17 points; 4. Right-handed; 5. After fully understanding the safety profile of TMS, willing to actively cooperate with the treatment, and providing signed informed consent from both the participant and their family members.

Exclusion criteria

Exclusion criteria: 1. Received MECT treatment within 6 months prior to enrollment. 2. Have a history of serious physical illness, or depression caused by other psychoactive substances or non-addictive substances. 3. Have metal or electronic devices implanted in the body, such as intracranial metal foreign bodies, cochlear implants, cardiac pacemakers, or stents, among other metal foreign bodies. 4. Have a risk of seizure onset, including a history of craniocerebral disease, head trauma, alcohol use disorder, abnormal electroencephalogram (EEG), MRI evidence of structural brain abnormalities, or a family history of epilepsy. 5. Acutely suicidal individuals. 6. Those with psychotic symptoms requiring combined use of antipsychotic medications.

Design outcomes

Primary

MeasureTime frame
The 17-item Hamilton Depression Rating Scale (HAMD-17) score;

Secondary

MeasureTime frame
Scores on other psychological and clinical symptom-related scales;Neurophysiological indices derived from multimodal neuroimaging;Scores of the Adverse Event Record Form;

Countries

China

Contacts

Public ContactXiaoli Liu

Affiliated Kangning Hospital of Ningbo University

1206207800@qq.com+86 574 26302510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026